Randol Mill Pharmacy, Arlington, TX

Is Randol Mill Pharmacy registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Randol Mill Pharmacy hold a Texas pharmacy license?

The Texas State Board of Pharmacy lists license 14456 for RANDOL MILL PHARMACY, ARLINGTON, status Active, as of Nov 15, 2026.

Has Randol Mill Pharmacy had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Sep 17, 2020), 1 warning letter close-out (Sep 28, 2022), 1 state handoff letter (Sep 28, 2022) and 1 FMD-145 letter (Sep 28, 2022) for Randol Mill Pharmacy. State board actions: the Texas State Board of Pharmacy file dated Nov 15, 2026 marks prior disciplinary orders on license 14456 (column DISP ACTN, value Y); the orders themselves are on the board’s license lookup and are not copied here. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Randol Mill Pharmacy
Location
Arlington, TX
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
1
Latest action on that page
Sep 28, 2022
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 NAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 7 observations
State board records
License found: 14456, Active

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Randol Mill Pharmacy, a 503A facility, with 5 dated actions.

Document
Sep 28, 2022Warning letter close-outWarning Letter Close Out Issued 09/28/2022FDA copy (archived)
Sep 28, 2022State handoff letterState Handoff Letter Issued 09/28/2022FDA copy (archived)
Sep 28, 2022FMD-145 letterFMD-145 Letter Issued 9/28/2022Not linked by FDA
Sep 17, 2020Warning letterWarning Letter (09/17/2020)fda.gov
Aug 6, 2019Form 483483 Issued 08/06/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Randol Mill Pharmacy, Arlington, TX (FEI number 3010177428), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
May 23, 2022No Action Indicated (NAI)Drug Quality Assurance (Drugs): No Action Indicated (NAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): No Action Indicated (NAI)30101774281170332
Aug 6, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30101774281098887

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 7 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 23, 2019 to Aug 6, 2019: 7 observations

Firm on the cover
Randol Mill Pharmacy, 1014 N Fielder Rd, Arlington, TX 76012 3149
FEI number
3010177428
Establishment type on the cover
Producer of Sterile and Non-steril e Drug Products
FDA district office on the cover
4040 North Central Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Personnel engaged in aseptic processing were observed with exposed hair.

Specifically, during my obervations of your firm's aseptic practices in compounding sterile drug product, Progesterone Cottonseed Oil 100 mg/ml injectable, 8mL vial, Lot 07232019@12, Expiry 8/22/2019, I observed your firm pharmacy teclmician's face with eyebrows exposed in the ISO 5 LAF hood.

Observation 2

Non-sterilized equipment was used in sterile drug production.

Specifically, while observing your firm's pharmacy technician lot preparation and aseptically process the drug product, Progesterone in Cottonseed Oil, 100 mg/mL Injectable, 8 mL vial, Lot 07232019@ 12, Expi1y 8/22/2019, Qty <Redacted B4> vials, the following aseptic processing equipment and materials were not sterilized and adequately disinfected prior to use in the ISO 5 LAF hood:

A. During set-up preparations for aseptically processing the drug product, Progesterone in Cottonseed Oil, 100 mg/mL Injectable, 8 mL via~Lot 07232019@12, I observed your firm's pharmacy technician fail to disinfect 2 out of the <Redacted B4> syringes when transferred from the ISO 7 to the ISO 5 LAF hood. Additionally, the technician failed to re-sanitize her hands after leaving and reentering the ISO 5 aseptic processing area a minimum of 6 times.

B. I observed your pharmacy technician use an unsterilized <Redacted B4> and metal cap crimper within your firm's the ISO 5 LAF hood. The <Redacted B4> is used to <Redacted B4> Both are stored within the ISO 7 Cleanroom underneath a stainless-steel table on top of a plastic container. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Your facility design allowed the influx of poor quality air into a higher classified area.

Specifically, your firm's cleanroom is inadequately designed such that it allows the influx of poor-quality air into the ISO 7 classified area. For example,

A. Your firm uses a portable A/C Unit as feed air into the ISO 7 Cleamoom HEPA, which is also is the location of your ISO 5 LAF. Your fnm has no maintenance records for the portable A/C. Your fnm failed to assess the air quality supplied by the A/C unit.

B. Your firm has a wall mounted HEP A filter in both the ISO 8 Anteroom and ISO 7 Cleamoom also contains your fn1n' s ISO 5 LAF hood. Your fnm failed to assess these areas for adequate airflow in the prevention of possible dead zones which may contribute to the contamination of sterile drug products.

C. During my walkthrough of your firm's aseptic processing area, I observed airflow vents between your ISO 7 Cleanroom to ISO 8 Anteroom and ISO 8 Anteroom to Non-classified area was obstructed . Your firm failed to ensure the airflow vents were unobstructed.

Observation 4

You produced hazardous drugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically, during a review your fmn's 2018 -2018 Sterile Compounding Log Book, I found your fnm aseptically processed the sterile drug product, Testosterone Cyp, 250MG/ML, 10 mL Vial, Lot# 01232018@3, Expity 07/22/2018. Your firm fail to use a deactivating agent on work surfaces after the production of hazardous drug product to prevent cross-contamination.

Observation 5

Procedures designed to prevent microbiological contamination of drug products purport ing to be sterile are not established and written.

Specifically, your firm failed to adequately design procedures to prevent microbiological contamination of sterile drug products. For example:

A. Your fnm failed to perform a <Redacted B4> test when using the <Redacted B4> to <Redacted B4> For example, your fnm aseptically processed the drug product, Methlcobalin W/PSV 1000 MCG/ML Injectable Lot# 07012019@1, BUD 12/28/2019, Qty <Redacted B4> Your firm's compounding specialist reported no <Redacted B4> test was performed on the <Redacted B4> . The <Redacted B4> was submitted to the firm's contract testing laboratory for sterility testing.

B. Your firm's media fill challenge is inadequate. Your film's media fill does not represent your firm's worse-case and most complex high-risk manipulation. Your firm uses <Redacted B4> Kit", which requires your firm's technician to aseptically process <Redacted B4>. <Redacted B4> vials. Your firm's compounding specialist reported your firm will aseptically manipulate up <Redacted B4> vials in one lot.

C. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, your firm failed to establish hold time specifications for the drug product, Testosterone Cyp, 250MG/ML, 10 mL Vial, Lot# 01232018@3, Expily 07/22/2018. Your firm's pharmacy technician reported, during production, the drug product was held in the non-sterile state over night in the ISO 5 LAF unit. Your firm's compounding specialist reported your firm failed to establish hold time specifications for this drug product.

Observation 7

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your firm failed to establish a written stability program for your firm's manufactured drug products to ensure product quality.

State board of pharmacy records

The Texas State Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatusPrior disciplinary orders (file flag)
14456Community PharmacyRANDOL MILL PHARMACYARLINGTONActiveYes

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.